GlassScriptPhysician profile
Nijal Sheth
NPI 1740422187
$97,443.83
in general payments reported to CMS, 2019-2025
34 companies · $62K in 2025
The $62K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $226 · 2021: $909 · 2022: $1,296 · 2023: $1,119 · 2024: $31K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $84K · Food and Beverage: $6,228 · Travel and Lodging: $4,362 · Education: $41.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,814.50 |
| Food and Beverage | $6,227.92 |
| Travel and Lodging | $4,362.41 |
| Education | $41.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $47,491.85 | 2023-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22,680.75 | 2021-2025 | Jardiance |
| Akebia Therapeutics INC | $21,050.98 | 2020-2025 | Vafseo, Auryxia |
| Astrazeneca Pharmaceuticals LP | $648.24 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $648.13 | 2019-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $554.19 | 2021-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $512.89 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $480.82 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $403.16 | 2023-2025 | |
| Vifor Pharma, INC. | $343.88 | 2019-2024 | Veltassa, Korsuva |
| Novo Nordisk INC | $326.74 | 2021-2025 | Ozempic, Rybelsus, Rivfloza |
| Horizon Therapeutics Plc | $309.45 | 2019-2023 | Krystexxa |
| Amgen INC. | $283.67 | 2020-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $254.98 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $230.52 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $229.47 | 2021-2023 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $133.68 | 2020-2024 | Ultomiris |
| Depuy Synthes Sales INC. | $105.58 | 2019 | |
| Fresenius USA Marketing, INC. | $83.22 | 2021-2025 | Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $80.33 | 2021-2022 | |
| Ardelyx, INC. | $78.39 | 2023-2024 | Ibsrela |
| Daiichi Sankyo INC. | $75.80 | 2021-2025 | Injectafer |
| Vantive US Healthcare LLC | $75.73 | 2025 | Renal - Extraneal Solution, Renal - Pd |
| Scpharmaceuticals INC. | $75.56 | 2024-2025 | |
| Nxstage Medical, INC. | $62.60 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $34.08 | 2025 | |
| Apellis Pharmaceuticals, INC. | $28.40 | 2025 | |
| Mallinckrodt Enterprises LLC | $27.86 | 2019 | |
| Cormedix INC. | $26.63 | 2024 | Defencath |
| Coala Life INC | $25.51 | 2023 | Coala Heart Monitor |
| Mannkind Corporation | $25.38 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $22.34 | 2023 | Crysvita |
| Ani Pharmaceuticals, INC. | $21.37 | 2022 | |
| Nestle Healthcare Nutrition INC. | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nijal Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.